Emerging roles of RNA m⁶A modification in multiple myeloma pathogenesis and treatment resistance (Review)

Area of Science:

• Hematologic Malignancy Research
• Epitranscriptomics
• Cancer Molecular Mechanisms

Background:

• Multiple myeloma (MM) is an incurable plasma cell malignancy with frequent relapse due to treatment resistance.
• Current therapies face challenges, necessitating the discovery of novel molecular drivers of MM pathogenesis and therapeutic failure.
• Epitranscriptomics, particularly N6-methyladenosine (m6A) RNA modification, is emerging as a key player in cancer biology.

Purpose of the Study:

• To review the current understanding of how m6A regulators influence multiple myeloma.
• To explore the role of m6A modification in MM heterogeneity, disease progression, and drug resistance.
• To discuss the therapeutic potential of targeting m6A pathways in MM.

Main Methods:

• Literature review synthesizing current knowledge on m6A regulators in MM.
• Analysis of m6A's impact on MM oncogenesis, signaling pathways, and bone marrow microenvironment interactions.
• Discussion of therapeutic strategies targeting m6A pathways.

Main Results:

• Dysregulation of the m6A machinery is implicated in MM heterogeneity, progression, and drug resistance.
• Specific m6A regulators modulate key signaling pathways and interactions within the bone marrow microenvironment.
• m6A modification influences MM cell responses to various therapies.

Conclusions:

• m6A modification is a critical factor in multiple myeloma pathogenesis and therapeutic resistance.
• Targeting m6A pathways presents a promising strategy to improve treatment outcomes in MM.
• m6A epitranscriptomics represents an important frontier for future MM research and therapy.